Hamai et al demonstrated that c-kit inhibition through imatinib (FDA-approved as first-line treatment for Ph+ CML) increased TRAIL-mediated proliferation impairment and apoptosis in a primary TRAIL-sensitive melanoma cell line but not in its metastatic TRAIL-resistant counterpart. This evidence concerns the gene TNFSF10 and melanoma.